PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Matairesinol alleviated cardiac hypertrophy and remodeling induced by pressure overload in rat and mouse models [PMID:39306883]
Nagilactone B exhibited potent anti-inflammatory effects against nitric oxide production in RAW 264.7 and HT-29 cells [PMID:34299601]
The compound 2,3-dihydro-4',4'''-di-O-methylamentoflavone showed a potent anti-tyrosinase effect in human epidermal melanocytes [PMID:17473463]
Various norditerpenes and dilactones exhibited anti-proliferative and cytotoxic activities against human solid tumor cell lines and P388 murine leukemia cells [PMID:29573148, PMID:19571410]
Evidence summary
PubMed sources
- 1.PMID: 39306883 (2024) — Matairesinol blunts adverse cardiac remodeling and heart failure induced by pressure overload by regulating Prdx1 and PI3K/AKT/FOXO1 signaling. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 2.PMID: 35814177 (2022) — The complete chloroplast genome sequence of Podocarpus macrophyllus (Podocarpaceae) and phylogenetic analysis. · Mitochondrial DNA. Part B, Resources
- 3.PMID: 36800928 (2024) — Phytochemical analysis and quality assessment of Podocarpus macrophyllus by UHPLC-DAD-ESI-MS and UHPLC-MS/MS MRM methods. · Natural product research
- 4.PMID: 34696735 (2021) — De novo transcriptome analysis provides insights into the salt tolerance of Podocarpus macrophyllus under salinity stress. · BMC plant biology
- 5.PMID: 31815964